Answers are grounded in this paper and cite their sources.
We evaluated an AI chatbot's ability to suggest diagnostic and therapeutic pathways for renal cell carcinoma (RCC) in a multidisciplinary tumor board (MDT). A retrospective analysis of 103 cases (2023-2024) found 62.1% agreement with MDT decisions (κ = 0.44, p< 0.001). Concordance was highest in when follow-up imaging was suggested (p = 0.001), with disease status influencing agreement (p = 0.004). These results suggest AI could assist in RCC case assessments, warranting further research.
No takes yet. Share an insight, caveat, or question.
Bertolo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: